Argenx Se (ARGX) Total Non-Current Liabilities (2016 - 2026)

Argenx Se's (ARGX) quarterly Total Non-Current Liabilities came in at $40.0 million in Q2 2026, down 99.89% YoY from $37.9 billion in Q2 2025, and up 2.56% on a QoQ basis from $39.0 million in Q4 2025.

Argenx Se (ARGX) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends

Argenx Se (ARGX) has 11 years of Total Non-Current Liabilities data on file, last reported at $40.0 million in Q2 2026.

  • Quarterly Total Non-Current Liabilities fell 99.89% year-over-year to $40.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $40.0 million (down 99.89% YoY) and the FY2025 annual result came in at $39.0 million, up 13.63% from the prior year.
  • Total Non-Current Liabilities climbed to $40.0 million in Q2 2026, from $39.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $37.9 billion in Q2 2025 to a low of $14.4 million in Q2 2022.
  • A 5-year average of $4.2 billion and a median of $34.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2025 — Total Non-Current Liabilities soared 109282.39% — and 2026, when it sank 99.89%.
  • Tracing ARGX's Total Non-Current Liabilities over 5 years: stood at $18.3 million in 2022, then gained by 20.09% to $22.0 million in 2023, then soared by 56.31% to $34.3 million in 2024, then climbed by 13.63% to $39.0 million in 2025, then climbed by 2.56% to $40.0 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $40.0 million (Q2 2026), $39.0 million (Q4 2025), and $37.9 billion (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 40.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 1.53 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.88 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.32 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.20 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.17 Bn
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn 378.37 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 40.00 Mn
Dec 31, 2025 39.00 Mn
Jun 30, 2025 37.94 Bn
Dec 31, 2024 34.32 Mn
Jun 30, 2024 34.68 Mn
Dec 31, 2023 21.96 Mn
Jun 30, 2023 17.95 Mn
Dec 31, 2022 18.29 Mn
Jun 30, 2022 14.42 Mn
Dec 31, 2021 14.81 Mn
Jun 30, 2021 17.05 Mn
Dec 31, 2020 267.56 Mn
Jun 30, 2020 228.32 Mn
Dec 31, 2019 246.43 Mn
Jun 30, 2019 271.20 Mn
Dec 31, 2018 7,989.77
Jun 30, 2018 29,836.11
Dec 31, 2017 1.72 Mn
Jun 30, 2017 1,099.55
Dec 31, 2016 10.87 Mn